Document is current
Any future updates will be listed below
-
Authors
Ehlers, Lars Holger https://orcid.org/0000-0001-6512-5566
Reinstrup, Nicoline Weinreich
Olesen, Renée Hangaard
Holm, Jens-Christian https://orcid.org/0000-0003-4653-342X
McEwan, Phil
Le Roux, Carel W. https://orcid.org/0000-0001-5521-5445
- License Information
-
More Information
Article History
Received: 24 June 2024
Revised: 1 October 2024
Accepted: 4 October 2024
First Online: 16 October 2024
Competing interests
: The current analysis was funded by a research grant from Novo Nordisk to Nordic Institute of Health Economics. The sponsor contributed to the design and the protocol of the study, but the academic authors made the final determination as to which analyses to present and how to best interpret them. LHE has received consultancy fees or research funding from AbbVie, AstraZeneca, Boehringer Ingelheim, Contura, Gilead, GSK, Janssen, Merck, Novartis, Novocure, Novo Nordisk, Pfizer, Radiometer, and Specsavers. ClR reports grants from the Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board; serves on advisory boards and speakers panels of Novo Nordisk, Roche, Herbalife, GI Dynamics, Eli Lilly, Johnson & Johnson, Glia, Irish Life Health, Boehringer Ingelheim, Currax, Zealand Pharma, Keyron, AstraZeneca, and Rhythm Pharma; is a member of the Irish Society for Nutrition and Metabolism outside the area of work commented on here; and provides obesity clinical care in the My Best Weight Clinic and Beyond BMI clinic and is a shareholder of these clinics. PM have received funding and honoraria from Novo Nordisk and other pharmaceutical companies. JCH have received honoraria from Novo Nordisk and Rhythm. JCH provides training and treatment. NWR and RHO have no competing interest to declare.
